Antibodies, Blocking

"Antibodies, Blocking" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)

Descriptor ID	D019138
MeSH Number(s)	D12.776.124.486.485.114.143 D12.776.124.790.651.114.143 D12.776.377.715.548.114.143
Concept/Terms	Antibodies, Blocking Antibodies, Blocking Blocking Antibodies Enhancing Antibodies Enhancing Antibodies Antibodies, Enhancing

Below are MeSH descriptors whose meaning is more general than "Antibodies, Blocking".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Blocking [D12.776.124.486.485.114.143]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Blocking [D12.776.124.790.651.114.143]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Blocking [D12.776.377.715.548.114.143]

Below are MeSH descriptors whose meaning is more specific than "Antibodies, Blocking".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antibodies, Blocking" by people in this website by year, and whether "Antibodies, Blocking" was a major or minor topic of these publications.

Bar chart showing 14 publications over 14 distinct years, with a maximum of 1 publications in 1997 and 1998 and 2000 and 2002 and 2003 and 2006 and 2008 and 2009 and 2010 and 2011 and 2013 and 2016 and 2017 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	0	1	1
2000	0	1	1
2002	1	0	1
2003	0	1	1
2006	0	1	1
2008	0	1	1
2009	0	1	1
2010	0	1	1
2011	0	1	1
2013	0	1	1
2016	0	1	1
2017	0	1	1
2021	1	0	1

Below are the most recent publications written about "Antibodies, Blocking" by people in Profiles.

Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, Kasper IR, Oliver B, Mielcarz DW, Kasper LH. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6).

View in: PubMed
Marshall NB, Lukomska E, Nayak AP, Long CM, Hettick JM, Anderson SE. Topical application of the anti-microbial chemical triclosan induces immunomodulatory responses through the S100A8/A9-TLR4 pathway. J Immunotoxicol. 2017 Dec; 14(1):50-59.

View in: PubMed
Cianci R, Lolli S, Pagliari D, Gambassi G, Frosali S, Marmo R, Melioli G, Orlando A, Newton EE, Serone E, Landolfi R, Pandolfi F, Frezza D. The involvement of IgH enhancer HS1.2 in the pathogenesis of Crohn's disease: how the immune system can influence a multifactorial disease. Eur Rev Med Pharmacol Sci. 2016 09; 20(17):3618-27.

View in: PubMed
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710.

View in: PubMed
Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother. 2012 Feb; 61(2):145-55.

View in: PubMed
Mueller M, Spangenberg HC, Kersting N, Altay T, Blum HE, Klenerman P, Thimme R, Semmo N. Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. J Hepatol. 2010 Jun; 52(6):800-11.

View in: PubMed
San Antonio JD, Zoeller JJ, Habursky K, Turner K, Pimtong W, Burrows M, Choi S, Basra S, Bennett JS, DeGrado WF, Iozzo RV. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. Am J Pathol. 2009 Sep; 175(3):1338-47.

View in: PubMed
Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M, Ravetch JV, Verbeek JS, Izui S. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol. 2008 Feb 01; 180(3):1948-53.

View in: PubMed
Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2):H517-31.

View in: PubMed
Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J, Tykocinski ML. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J Immunol. 2003 Jun 15; 170(12):5842-50.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement